<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03194815</url>
  </required_header>
  <id_info>
    <org_study_id>SINAPPS 2</org_study_id>
    <nct_id>NCT03194815</nct_id>
  </id_info>
  <brief_title>IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2</brief_title>
  <acronym>SINAPPS2</acronym>
  <official_title>A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients With Antibody-associated Psychosis (SINAPPS2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised phase II double-blinded placebo-controlled trial designed to explore the utility
      of immunotherapy for patients with acute psychosis associated with anti-neuronal membranes
      (NMDA-receptor or Voltage Gated Potassium Channel).

      Primary objective: To test the efficacy of immunotherapy (IVIG and rituximab) for patients
      with acute psychosis associated with anti-neuronal membranes.

      Secondary objective: To test safety of immunotherapy (IVIG and rituximab) for patients with
      acute psychosis associated with anti-neuronal membranes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators propose a randomised double-blinded placebo-controlled trial to test the
      hypothesis that immunotherapy is an effective treatment of antibody-associated psychosis,
      either first episode of psychosis or relapse following previous remission. Immunotherapy for
      the trial consists of one cycle of intravenous immunoglobulin (IVIG: 2g/kg over days 1-4)
      followed by two infusions of 1g rituximab (at day 28-35, and then 14 days after the first
      infusion). The rationale for this regime is that it combines a rapid-action treatment (IVIG)
      to induce remission with a longer-action therapy (rituximab) to maintain remission. It is
      based on a protocol where elimination of circulating antibodies is the treatment goal, namely
      &quot;desensitisation&quot; of potential transplant patients who have multiple anti-HLA antibodies
      capable of inducing hyperacute rejection and also being tested in various trials on
      clinicaltrials.gov (NCT00642655, NCT01178216, and NCT01502267). Blinding is required to
      minimise placebo responses in a trial based on symptomatology.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to start of remission</measure>
    <time_frame>up to 18 months</time_frame>
    <description>remission defined as Positive and Negative Syndrome Scale (PANSS) score 3 or less on PANSS items P1, P2, P3, N1, N4, N6, G5 and G9 sustained for 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first treatment response (whether sustained or not)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Treatment response defined as score of 3 or less on each of the following PANSS items: P1, P2, P3, N1, N4, N6, G5, and G9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>18 months</time_frame>
    <description>Relapse rate is defined as a score 4 or more on PANSS items P1, P2, P3, N1, N4, N6, G5, and G9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse effects</measure>
    <time_frame>18 months</time_frame>
    <description>total number of patient reported adverse effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reaching 20% reduction in PANSS total score</measure>
    <time_frame>12 months</time_frame>
    <description>20% reduction in the PANSS total score (all PANNS items included)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reaching 30% reduction in PANSS total score</measure>
    <time_frame>12 months</time_frame>
    <description>30% reduction in the PANSS total score (all PANNS items included)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reaching 40% reduction in PANSS total score</measure>
    <time_frame>12 months</time_frame>
    <description>40% reduction in the PANSS total score (all PANNS items included)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Clinical Global Impression Scale in Schizophrenia (CGI-Schizophrenia)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in CGI-Schizophrenia scores from baseline to month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Young Mania Rating Scale (YMRS)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in YMRS total score from baseline to month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Antipsychotic Non-Neurological Side-Effects Rating Scale (ANNSERS)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in ANNSERS total score from baseline to month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Brief Assessment of Cognition in Schizophrenia (BACS)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in BACS scores from baseline to month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Global Assessment of Functioning scale (GAF)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in the GAF score from baseline to month 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Psychosis</condition>
  <condition>Autoimmune Encephalitis</condition>
  <arm_group>
    <arm_group_label>Intravenous immunoglobulin and Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One cycle of intravenous immunoglobulin (IVIG) 2g/kg over 2-5 days (days 1-5) followed by (b) two infusions of 1g rituximab (the first infusion starting between days 28-35, and the second infusion 14 days later), each with 100mg methylprednisolone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One cycle of 0.9% saline solution over 2-5 days (days 1-5) followed by (b) two infusions of placebo solution alongside placebo pill - in equal volumes to steroid pre-medication and rituximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous immunoglobulin</intervention_name>
    <description>This is a blood product containing antibodies from thousands of healthy donors.</description>
    <arm_group_label>Intravenous immunoglobulin and Rituximab</arm_group_label>
    <other_name>IVIG</other_name>
    <other_name>Intratect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This is the control, or sham, treatment</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab is a type of biological therapy. It removes B-cells and helps to reduce the inflammation</description>
    <arm_group_label>Intravenous immunoglobulin and Rituximab</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute psychosis &gt;2 weeks, either first episode or relapse after remission (remission
             defined as PANSS≤3 on PANSS items P1, G9, P3, P2, G5, N1, N4, N6 for previous 6
             months)

          -  Serum or CSF neuronal membrane autoantibodies at pathological levels (including NMDAR,
             LGI1 and other)

          -  PANSS ≥4 on P1, G9, P3, P2, G5, N1, N4, N6.

        Exclusion Criteria:

          -  Current episode of psychosis greater than 24 months duration

          -  Co-existing severe neurological disease

          -  Evidence of current acute encephalopathy

          -  Hepatitis or HIV infection, pregnancy

          -  Contraindications to any trial drug

          -  Concurrent enrolment in another CTIMP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alasdair Coles, PhD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alastdair Coles, PhD FRCP</last_name>
    <phone>+44 (0)1223 762016</phone>
    <email>ajc1020@medschl.cam.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Belinda Lennox, DM MRCPsych</last_name>
    <phone>: +44(0)1865 613145</phone>
    <email>belinda.lennox@psych.ox.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cambridge University Hospitals</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alasdair Coles, PhD FRCP</last_name>
      <phone>+44 (0)1223 762016</phone>
      <email>ajc1020@medschl.cam.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals Nhs Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zandi, PhD MRCP</last_name>
      <email>m.zandi@ucl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospitals</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belinda Lennox, DM MRCPsych</last_name>
      <phone>: +44(0)1865 613145</phone>
      <email>belinda.lennox@psych.ox.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://sinapps.org.uk</url>
    <description>SINAPPS Group website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>Alasdair Coles</investigator_full_name>
    <investigator_title>Revd. Prof. Alasdair Coles, Chief Investigator</investigator_title>
  </responsible_party>
  <keyword>Psychosis</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Autoantibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

